S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(-0.05%) $0.926
USD/NOK
(-0.09%) $10.83
USD/GBP
(-0.08%) $0.792
USD/RUB
(-0.21%) $92.38

Realtime updates for I-Mab [IMAB]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Upcoming Earnings Alert

Quarter results today
(bmo 2024-03-29)

Expected move: +/- 14.19%

BUY
33.33%
return -0.53%
SELL
0.00%
return 10.67%
Last Updated28 Mar 2024 @ 16:00

-0.53% CNY 1.860

BUY 64812 min ago

@ CNY1.720

Issued: 13 Feb 2024 @ 09:31


Return: 8.14%


Previous signal: Feb 9 - 10:06


Previous signal: Sell


Return: -6.01 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial...

Stats
Today's Volume 193 670
Average Volume 541 070
Market Cap 154.36M
EPS CNY0 ( 2024-03-28 )
Last Dividend CNY0 ( N/A )
Next Dividend CNY0 ( N/A )
P/E -0.500
ATR14 CNY0.00600 (0.32%)

Volume Correlation

Long: -0.13 (neutral)
Short: -0.72 (moderate negative)
Signal:(47.802) Neutral

I-Mab Correlation

10 Most Positive Correlations
ATNX0.884
CGO0.88
BPRN0.88
GFAI0.874
DRCT0.853
CFRX0.848
BELFA0.842
APLD0.84
CNTY0.838
CVCY0.834
10 Most Negative Correlations
DWSH-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

I-Mab Correlation - Currency/Commodity

The country flag 0.74
( moderate )
The country flag 0.73
( moderate )
The country flag 0.00
( neutral )
The country flag 0.73
( moderate )
The country flag 0.00
( neutral )
The country flag -0.46
( neutral )

I-Mab Financials

Annual 2022
Revenue: CNY-221.56M
Gross Profit: CNY-248.80M (112.29 %)
EPS: CNY-29.23
Q2 2023
Revenue: CNY2.84M
Gross Profit: CNY2.84M (100.00 %)
EPS: CNY-1.340
Q4 2022
Revenue: CNY-1.76B
Gross Profit: CNY-1.79B (101.54 %)
EPS: CNY-39.20
Q4 2020
Revenue: CNY1.54B
Gross Profit: CNY0.00 (0.00 %)
EPS: CNY8.55

Financial Reports:

No articles found.

I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators